http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101856363-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa783eb077323e5ca6a1d18544900715
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
filingDate 2009-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2013-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1733d66e84acf5f91a708b87994b8a52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dcd476e431d5f4b42344c96ec329723
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb04b58997c6b7fc672c2bc2c7dc5a88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c22b59ab4c05b4d3af94d6115b6c0ea7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e5a7c7baddfe1444cc3c1c2e592b1dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7186a3cc7bf5b2f346db12c5e480ae23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f80451afe5e50f9f2d89cde304d1d69b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ef253e427a447ce48294c8337bfed3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e29c9af3c492fba402289c0196b705df
publicationDate 2013-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-101856363-B
titleOfInvention Application of Bortezomib in preparing drugs for curing POEMS syndrome
abstract The invention relates to the technical field of medicaments, which discloses an application of Bortezomib in preparing drugs for curing POEMS syndrome and provides a drug capable of effectively curing POEMS syndrome, thus providing an effective, safe and novel curing approach for curing the POEMS syndrome, i.e. a proteasome inhibitor (Bortezomib) targeted therapy approach.
priorityDate 2009-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1046
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527393
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492800
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54675776
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503663
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID3735
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID387447
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID3735
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419478079
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222786
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423512670

Total number of triples: 37.